Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
The conversation discusses using oral Minoxidil, a vasodilator, for both Raynaud's Syndrome and hair loss. It also inquires about other hair loss treatments that improve blood flow.
A 35-year-old male is experiencing diffuse thinning and is using finasteride, topical minoxidil, and dutasteride. He is considering a hair transplant but is advised to wait and continue with medications for now.
A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.
PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.
Finasteride is not effectively stopping hair loss for the user, who is considering alternatives like Dutasteride, Minoxidil, and microneedling, but is hesitant about surgery or hair systems. The user expresses frustration with the lack of effective treatments for male pattern baldness.
A female user experiences severe side effects from topical finasteride and pumpkin seed oil for hair loss, leading to rapid hair thinning after stopping use. She seeks advice on tapering off treatments to manage hair sensitivity and maintain hair health.
A user is seeking advice on a new topical hair loss treatment containing Minoxidil 3%, Finasteride 0.3%, Progesterone 1%, Hydrocortisone butyrate 0.1%, and Ketoconazole 0.5%. They are concerned about the systemic absorption of Finasteride and plan to do blood tests and a spermiogram before starting.
The conversation discusses concerns about using cordyceps while on dutasteride due to potential DHT increase, with OP experiencing hair loss after using creatine. OP is advised to stop creatine and give dutasteride more time to evaluate its effectiveness.
Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.
The user is frustrated because their current dutasteride treatment isn't effective due to poor absorption, leading to hair loss progression. They consider switching to gel capsules and discuss using minoxidil and biotin alongside dutasteride.
The user is experiencing diffuse thinning and has started taking 0.5mg dutasteride and 5mg oral minoxidil daily, planning to wait a year before considering a hair transplant. They are advised to be patient, consult with doctors, and see how the medication affects their hair density before proceeding with surgery.
Clascoterone powder is now available, but it's expensive and not widely discussed due to past ineffective results at higher concentrations. Users are skeptical about its effectiveness and are seeking reliable sources.
Bicalutamide blocks androgen receptors, preventing testosterone and DHT from binding, which can help with hair loss but may cause feminization. It is not recommended for those who do not want feminization effects.
Users discuss making topical finasteride solutions by dissolving crushed tablets in ethanol and propylene glycol, with concerns about residue affecting effectiveness. They also mention using minoxidil and oral finasteride, noting some hair regrowth and no side effects from topical use.
The conversation discusses hair loss treatment options, focusing on finasteride and its potential effects on gynecomastia. The user is considering finasteride while managing hormone levels with supplements like boron, vitamin D, zinc, magnesium, and P5P, and is advised to consult an endocrinologist for further evaluation.
Using PP405 and Clascoterone after a hair transplant may not cause issues if the transplant didn't achieve native density, but could lead to competition for blood supply if it did. Some users suggest waiting for these drugs to be available, as they might not significantly impact blood supply or regrowth.
Oral minoxidil caused dark circles and visible veins for the user, who responded quickly to the treatment but lowered the dose to reduce side effects. Despite using finasteride and tretinoin, the user is considering stopping minoxidil if the side effects persist.
RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.
The user started using finasteride and minoxidil for hair loss, noting past success with minoxidil alone but now needing a DHT blocker. They experienced side effects like chest pain and considered reducing the finasteride dose.
Dutasteride and finasteride can cause watery ejaculate, which may persist for some users. Zinc supplements or switching to topical treatments are suggested to alleviate this side effect.
Oral minoxidil can cause serious heart issues like cardiac hypertrophy and arrhythmias, prompting some users to reduce dosage or switch to topical treatments. Despite significant hair regrowth, side effects such as shortness of breath and chest pains are common concerns.
A 23-year-old male is experiencing aggressive hair loss despite using 1mg finasteride and 4.5mg minoxidil, with limited progress and side effects like fluid retention. Suggestions include trying dutasteride, microneedling with topical minoxidil, and considering hair systems or a transplant in the future.
Minoxidil can cause dark circles and aging appearance in some users, leading them to stop its use despite hair regrowth benefits. Some users suggest reducing dosage or switching to oral minoxidil to minimize side effects.
SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.
A user is discussing their experience with finasteride for diffuse thinning without a receding hairline, noting a massive shedding phase in the fourth month that is now slowing down. Other replies are off-topic and not relevant to the treatment discussion.
User experienced good results with topical finasteride, noting reduced DHT and increased testosterone. They plan to revert to a lower dosage after observing slight libido reduction.
The conversation is about hair loss and the type of hair brush used by those experiencing diffused thinning. The discussion includes treatments like Minoxidil, finasteride, and RU58841.